Ignite Creation Date:
2024-05-06 @ 3:22 PM
Last Modification Date:
2024-10-26 @ 1:48 PM
Study NCT ID:
NCT04616534
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-09
First Post:
2020-11-04
Brief Title:
Testing the Addition of an Anti-cancer Drug Elimusertib BAY 1895344 ATR Inhibitor to the Chemotherapy Treatment Gemcitabine for Advanced Pancreatic and Ovarian Cancer and Advanced Solid Tumors
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Unresectable Pancreatic Adenocarcinoma |
| Advanced Fallopian Tube Carcinoma |
| Advanced Malignant Solid Neoplasm |
| Advanced Ovarian Carcinoma |
| Advanced Pancreatic Adenocarcinoma |
| Advanced Primary Peritoneal Carcinoma |
| Fallopian Tube High Grade Serous Adenocarcinoma |
| Metastatic Pancreatic Adenocarcinoma |
| Ovarian High Grade Serous Adenocarcinoma |
| Platinum-Resistant Fallopian Tube Carcinoma |
| Platinum-Resistant Ovarian Carcinoma |
| Platinum-Resistant Primary Peritoneal Carcinoma |
| Primary Peritoneal High Grade Serous Adenocarcinoma |
| Stage II Pancreatic Cancer AJCC v8 |
| Stage III Fallopian Tube Cancer AJCC v8 |
| Stage III Ovarian Cancer AJCC v8 |
| Stage III Pancreatic Cancer AJCC v8 |
| Stage III Primary Peritoneal Cancer AJCC v8 |
| Stage IV Fallopian Tube Cancer AJCC v8 |
| Stage IV Ovarian Cancer AJCC v8 |
| Stage IV Pancreatic Cancer AJCC v8 |
| Stage IV Primary Peritoneal Cancer AJCC v8 |
Keywords: